225. 先天性腎性尿崩症
[臨床試験数:12,薬物数:45(DrugBank:17),標的遺伝子数:30,標的パスウェイ数:63

Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-002204-38-DK
(EUCTR)
24/11/202007/05/2020Treatment of the genetic disease nephrogenic diabetes insipidus with the antifungal drug FluconazoleTreatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication Nephrogenic diabetes insipidus
MedDRA version: 21.0;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
INN or Proposed INN: Fluconazole
Other descriptive name: FLUCONAZOLE
Claus BistrupNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
10Phase 2Denmark
2JPRN-jRCTs031180369
12/04/201818/03/2019Tolvaptan for nephrogenic diabetes insipidusExploratory study of tolvaptan use for nephrogenic diabetes insipidus caused by mutation in vasopressin type 2 receptor - Tolvaptan use for NDI by V2R mutation Nephrogenic diabetes insipidus
Nephrogenic diabetes insipidus, polyuria;D018500
Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days.Makita NorikoNULLRecruiting>= 20age oldNot applicableBoth3Japan
3EUCTR2016-001591-30-DK
(EUCTR)
06/11/201709/03/2017 Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafil Treatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafil Nephrogenic diabetes insipidus because of AVP2R-mutation
MedDRA version: 20.0;Level: LLT;Classification code 10012626;Term: Diabetes nephrogenic (excludes glycosuria);System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Odense University HospitalNULLNot Recruiting Female: no
Male: yes
2Phase 2Denmark
4NCT02967653
(ClinicalTrials.gov)
July 13, 201715/11/2016Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes InsipidusAtorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled TrialLithium Use, Nephrogenic Diabetes InsipidusDrug: AtorvastatinLady Davis InstituteNULLCompleted18 Years85 YearsAll60Phase 2Canada
5JPRN-UMIN000021708
2016/04/1818/04/2016A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. - A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor geneAdministration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days.Department of Nephrology and Endocrinology, The University of Tokyo HospitalNULLRecruiting20years-oldNot applicableMale and Female3Not selectedJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02460354
(ClinicalTrials.gov)
September 201529/5/2015Metformin and Congenital Nephrogenic Diabetes InsipidusUse of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI)Diabetes InsipidusDrug: MetforminEmory UniversityNULLTerminated18 YearsN/AMale2Phase 1United States
7EUCTR2012-001809-24-NL
(EUCTR)
31/07/201306/09/2012A diminished concentrating ability of the kidneys due to lithium prescription: how many and whom is affected?Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test - Nephrogenic diabetes insipidus (NDI) in lithium treated patients lithium-induced urinary concentrating defects (nephrogenic diabetes insipidus)
MedDRA version: 15.0;Level: LLT;Classification code 10050501;Term: Lithium toxicity;System Organ Class: 10022117 - Injury, poisoning and procedural complications
MedDRA version: 15.0;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses
Product Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses
Product Code: SUB21605
INN or Proposed INN: desmopressin acetate trihydrate
Other descriptive name: DESMOPRESSIN ACETATE TRIHYDRATE
Radboud University Nijmegen Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
8EUCTR2011-005970-41-NL
(EUCTR)
27/02/201208/02/2012The effect of the drug acetazolamide on excessive urine production due to a diminished concentrating ability of the kidney as a result of the use of lithium in patients with an affective disorder: a pilot studyThe effect of acetazolamide on lithium-induced nephrogenic diabetes insipidus in patients with an affective disorder: a pilot study lithium-induced nephrogenic diabetes insipidus
MedDRA version: 14.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 10038359 - Renal and urinary disorders
MedDRA version: 14.1;Classification code 10050501;Term: Lithium toxicity;System Organ Class: 10022117 - Injury, poisoning and procedural complications;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Acetazolamide Sandoz 250
Other descriptive name: ACETAZOLAMIDE
Radboud University Nijmegen Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
9EUCTR2006-003360-56-DK
(EUCTR)
28/08/200907/07/2009Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDYFarmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY Kongenit nefrogen diabetes insipidus
MedDRA version: 14.1;Level: PT;Classification code 10068304;Term: Congenital nephrogenic diabetes insipidus;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Trade Name: Confortid
INN or Proposed INN: INDOMETACIN
Trade Name: Losec
INN or Proposed INN: OMEPRAZOLE MAGNESIUM
Trade Name: Viagra
Other descriptive name: SILDENAFIL CITRATE
Trade Name: Miacalcic
Other descriptive name: CALCITONIN (SALMON)
Trade Name: Spirix
Other descriptive name: SPIRONOLACTONE
Trade Name: Esidrix
Product Name: Esidrix
INN or Proposed INN: HYDROCHLOROTHIAZIDE
Dept. of Pediatrics, The Childrens Hospital, DenverNULLNot RecruitingFemale: no
Male: yes
40Denmark
10NCT00478335
(ClinicalTrials.gov)
May 200723/5/2007Pharmacologic Treatment of Congenital Nephrogenic Diabetes InsipidusPharmacologic Treatment of Congenital Nephrogenic Diabetes InsipidusNephrogenic Diabetes InsipidusDrug: sildenafil;Drug: calcitonin;Drug: hydrochlorothiazide/amiloride;Drug: indomethacin;Drug: Placebo for sildenafil;Drug: placebo for calcitoninUniversity of Colorado, DenverUniversity of AarhusCompleted5 Years25 YearsMale4N/AUnited States;Denmark
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2006-001202-84-NL
(EUCTR)
01/02/200731/01/2007Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDIComparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI Lithium-induced Nephrogenic Diabetes Insipidus
MedDRA version: 9.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic
Trade Name: Midamor
Product Name: Amiloride
Trade Name: Hydrochloorthiazide
Product Name: hydrochloorthiazide
Radboud University Nijmegen Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Netherlands
12NCT00004360
(ClinicalTrials.gov)
September 199518/10/1999Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes InsipidusDiabetes Insipidus, NephrogenicDrug: chlorothiazideNational Center for Research Resources (NCRR)Northwestern UniversityCompleted6 Months70 YearsBothN/ANULL